GlassScriptPhysician profile
Rizwan K Moinuddin
NPI 1275568578
$23,104.05
in general payments reported to CMS, 2019-2025
26 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,040 · 2020: $4,171 · 2021: $1,269 · 2022: $8,667 · 2023: $1,596 · 2024: $656 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $10,038.91 | 2019-2023 | Krystexxa |
| Outset Medical INC | $7,614.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $899.46 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $746.42 | 2020-2022 | |
| Travere Therapeutics, INC. | $626.55 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $434.08 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $413.93 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $342.46 | 2019-2025 | Farxiga, Lokelma |
| Medtronic, INC. | $293.70 | 2022-2023 | Ellipsys Vascular Access System |
| Amgen INC. | $291.80 | 2019-2024 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $278.60 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $236.38 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $227.39 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $103.53 | 2022 | |
| Vifor Pharma, INC. | $78.40 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $74.97 | 2019 | |
| Ardelyx, INC. | $65.49 | 2023-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $54.69 | 2022 | |
| Aurinia Pharma U.S., INC. | $53.74 | 2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $53.54 | 2024 | |
| Alexion Pharmaceuticals, INC. | $48.06 | 2019-2020 | |
| Lilly USA, LLC | $44.26 | 2025 | Zepbound, Mounjaro, Jardiance |
| Daiichi Sankyo INC. | $38.14 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $16.41 | 2019 | |
| Shire North American Group INC | $15.35 | 2019 | |
| Renalytix Ai, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Moinuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.